Table 1 Baseline patient characteristics
Variable | Values |
|---|---|
Age (years) | 51.1 ± 9.4 |
Sex | |
Male | 123 (65.4) |
Female | 65 (34.6) |
Duration of diabetes (years) | 7.3 ± 4.9 |
Body weight (kg) | 82.5 ± 14.6 |
BMI (kg/m2) | 30.0 ± 4.4 |
Systolic blood pressure (mmHg) | 132.3 ± 14.1 |
Diastolic blood pressure (mmHg) | 80.6 ± 11.9 |
HbA1c (NGSP, %) | 7.8 ± 0.7 |
HbA1c (mmol/mol) | 62.1 ± 7.5 |
Fasting plasma glucose (mg/dl) | 156.2 ± 39.6 |
Current smokers | 50 (26.7) |
Drinking | 89 (47.3) |
eGFR (ml/min/1.73 m2) | |
90 ≤ | 65 (37.6) |
60 ≤, < 90 | 92 (53.2) |
45 ≤, < 60 | 15 (8.7) |
< 45 | 1 (0.6) |
Complications | |
Diabetic retinopathy | 22 (11.8) |
Simple | 13 (7.0) |
Pre-proliferative | 3 (1.6) |
Proliferative | 6 (3.2) |
Diabetic nephropathy | 53 (28.2) |
Diabetic neuropathy | 20 (10.6) |
Macrovascular complications | 0 (0.0) |
Kidney disease | 5 (2.7) |
Liver disease | 51 (27.1) |
Hypertension | 108 (57.4) |
Dyslipidemia | 125 (66.5) |
Oral hypoglycemic agents | 185 (98.4) |
Sulphonylureas | 68 (36.2) |
Biguanides | 137 (72.9) |
α-Glucosidase inhibitors | 27 (14.4) |
Glinides | 7 (3.7) |
DPP-4 inhibitors | 129 (68.6) |
Thiazolidinediones | 31 (16.5) |
Antihypertensive agents | 102 (54.3) |
Antidyslipidemic agents | 96 (51.1) |
Antithrombotic agents | 6 (3.2) |